Effect of Clopidogrel Added to Aspirin in Patients with Atrial Fibrillation

The ACTIVE Investigators·2009·New England Journal of Medicine
DOI 10.1056/nejmoa0901301

Cited by (1,000)

Items 801–900 of 1,000

  1. Effectiveness of Only Aspirin or Clopidogrel Following Percutaneous Left Atrial Appendage Closure
    Jussi-Pekka Pouru, Samuli Jaakkola, Juha Lund, Fausto Biancari, Antti Saraste, Juhani K.E. Airaksinen · 2019 · The American Journal of Cardiology
  2. Analysis of microRNA signatures in ischemic stroke thrombus
    Jeong‐Min Kim, Jun Soo Byun, Jiah Kim, Moo‐Seok Park, Soon Auck Hong, Taek-Kyun Nam, Hyun Ho Choi, Sungguan Hong, Su‐Hyun Han, Hae-Bong Jeong et al. · 2021 · Journal of NeuroInterventional Surgery
  3. Risk of Major Bleeding in Patients With Atrial Fibrillation Taking Dronedarone in Combination With a Direct Acting Oral Anticoagulant (From a U.S. Claims Database)
    Sampada K. Gandhi, James A. Reiffel, Rania Boiron, Mattias Wieloch · 2021 · The American Journal of Cardiology
  4. Therapeutic Management of Recurrent Peptic Ulcer Disease
    Raymond S. Y. Tang, Francis K.L. Chan · 2012 · Drugs
  5. Personalizing oral anticoagulant treatment in patients with atrial fibrillation
    Piera Capranzano, Eligio Miccichè, Lucia D’Urso, Fiorella Privitera, Corrado Tamburino · 2013 · Expert Review of Cardiovascular Therapy
  6. Oral antiplatelet agents in cardiovascular disease
    Joseph Pultar, Patricia Pia Wadowski, Simon Panzer, Thomas Gremmel · 2018 · VASA
  7. The ACTIVE Pursuit of Stroke Prevention in Patients with Atrial Fibrillation
    Alan S. Go · 2009 · New England Journal of Medicine
  8. New-onset atrial fibrillation after recent coronary stenting: Warfarin or non-vitamin K-antagonist oral anticoagulants to be added to aspirin and clopidogrel? A viewpoint
    Andrea Rubboli, Stefan Agewall, Kurt Huber, Gregory Y.H. Lip · 2015 · International Journal of Cardiology
  9. Efficacy and safety of novel oral anticoagulants in clinical practice: a report from three centers in Sweden
    Ashkan Labaf, Martin Carlwe, Peter J. Svensson · 2014 · Thrombosis Journal
  10. A novel approach indirectly comparing benefit–risk balance across anti-thrombotic therapies in patients with atrial fibrillation
    Ariel Dogliotti, Robert Patrick Giugliano · 2015 · European Heart Journal - Cardiovascular Pharmacotherapy
  11. Anticoagulation management in nonvalvular atrial fibrillation: current and future directions
    Jelena Kornej, Tatjana Potpara, Gregory Y.H. Lip · 2013 · Polskie Archiwum Medycyny Wewnętrznej
  12. Challenges of Anticoagulant Therapy in Atrial Fibrillation—Focus on Gastrointestinal Bleeding
    Alina Scridon, Alkora Ioana Balan · 2023 · International Journal of Molecular Sciences
  13. Arterial Thromboembolism in Patients With Atrial Fibrillation and CHA 2 DS 2 -VASc Score 1: A Nationwide Study
    Lauge Østergaard, Jonas Bjerring Olesen, Jeppe Kofoed Petersen, Lukas Schak Nielsen, Søren Lund Kristensen, Morten Schou, Lars Køber, Emil Loldrup Fosbøl · 2023 · Circulation
  14. REVIEW: New Approaches to Atrial Fibrillation Management: Treat the Patient, not the ECG
    Arnold Pintér, Paul Dorian · 2010 · Cardiovascular Therapeutics
  15. Effect of Esomeprazole With/Without Acetylsalicylic Acid, Omeprazole and Lansoprazole on Pharmacokinetics and Pharmacodynamics of Clopidogrel in Healthy Volunteers
    Tommy Andersson, Péter Nagy, Mohammad Niazi, Sven Nylander, Hal Galbraith, Santosh Ranjan, Lars C. Wallentin · 2014 · American Journal of Cardiovascular Drugs
  16. Guía de práctica clínica de la ESC sobre diabetes, prediabetes y enfermedad cardiovascular, en colaboración con la European Association for the Study of Diabetes
    Lars Rydén, Grupo de Trabajo de la Sociedad Europea de Cardiología sobre diagnóstico y tratamiento de la cardiopatía isquémica estable, Peter J. Grant, Stefan D. Anker, Christian Berne, Francesco Cosentino, Nicolas Danchin, Christi Deaton, Javier Escaned, Hans Peter Hammes et al. · 2014 · Revista Española de Cardiología
  17. Stroke risk stratification scores in atrial fibrillation: current recommendations for clinical practice and future perspectives
    Joseph Durrant, Gregory Y.H. Lip, Deirdre A. Lane · 2012 · Expert Review of Cardiovascular Therapy
  18. Feasibility of TEE-guided stroke risk assessment in atrial fibrillation—background, aims, design and baseline data of the TIARA pilot study
    for the TIARA pilot study group, Trang Dinh, Leo H. B. Baur, Ron Pisters, Otto Kamp B, Freek W.A. Verheugt, Joep L.R.M. Smeets, Emile C. Cheriex, Robert G. Tieleman, Martin H. Prins et al. · 2011 · Netherlands Heart Journal
  19. Rivaroxaban for stroke prevention in atrial fibrillation: a critical review of the ROCKET AF trial
    Jeremy S. Paikin, Joshua J. Manolakos, John W. Eikelboom · 2012 · Expert Review of Cardiovascular Therapy
  20. Adverse skin reaction caused by dabigatran.
    M A Cakmak, Şevki Şahin, N Cinar, S Karsidag · 2014 · PubMed
  21. Thrombolytic Therapy in Severe Cardioembolic Stroke After Reversal of Dabigatran with Idarucizumab: Case Report and Literature Review
    Yuichiro Ohya, Noriko Makihara, Kayo Wakisaka, Takao Morita, Tetsuro Ago, Takanari Kitazono, Hitonori Takaba · 2018 · Journal of Stroke and Cerebrovascular Diseases
  22. Registry of left atrial appendage closure and initial experience with intracardiac echocardiography
    Liliana Reis, Luís Paiva, Marco Aurélio de Souza Costa, Joana Silva, Rogerio P. Teixeira, Ana Botelho, Paulo Dinis, Marta Madeira, Joana Maria Ribeiro, José Nascimento et al. · 2018 · Revista Portuguesa de Cardiologia (English Edition)
  23. Thromboembolic events around the time of cardioversion for atrial fibrillation in patients receiving antiplatelet treatment in the ACTIVE trials
    William F. McIntyre, Stuart J. Connolly, Jia Wang, Simona Masiero, Alexander Philipp Benz, David Conen, Jorge A. Wong, Heather Beresh, Jeff S. Healey · 2019 · European Heart Journal
  24. Left Atrial Appendage Occlusion: Past, Present and Future
    Wern Yew Ding, John M. Mandrola, Dhiraj Gupta · 2020 · Thrombosis and Haemostasis
  25. Diagnosis, prevention, and treatment of cardiovascular diseases in people with type 2 diabetes and prediabetes: a consensus statement jointly from the Japanese Circulation Society and the Japan Diabetes Society
    the directors of the JCS, JDS, Eiichi Araki, Atsushi Tanaka, Nobuya Inagaki, Hiroshi Ito, Kohjiro Ueki, Toyoaki Murohara, Kenjiro Imai, Masataka Sata, Takehiro Sugiyama et al. · 2020 · Diabetology International
  26. Left Atrial Appendage Occlusion for Stroke Prevention
    Oluseun O. Alli, David R. Holmes · 2012 · Current Problems in Cardiology
  27. Dabigatran in Clinical Practice
    Rangadham Nagarakanti, Christopher Randall Ellis · 2012 · Clinical Therapeutics
  28. Comparative effect of clopidogrel and aspirin versus aspirin alone on laboratory parameters: a retrospective, observational, cohort study
    Yasuo Takahashi, Yayoi Nishida, Tomohiro Nakayama, Satoshi Asai · 2013 · Cardiovascular Diabetology
  29. Global Thrombosis Test – a possible monitoring system for the effects and safety of dabigatran
    Kazunori Otsui, Diana Adrienne Gorog, Junichiro Yamamoto, Takayuki Yoshioka, Sachiyo Iwata, Atsushi Suzuki, Toru Ozawa, Asumi Takei, Nobutaka Inoue · 2015 · Thrombosis Journal
  30. Individualized approaches to thromboprophylaxis in atrial fibrillation
    Oliver Jonathan Ziff, A. John Camm · 2015 · American Heart Journal
  31. Advances in management
    Jonathan R. Dalzell, Mark Colquhoun Petrie, R. S. Gardner · 2010 · BMJ
  32. Outcomes After Cardioversion in Atrial Fibrillation Patients Treated with Non-Vitamin K Antagonist Oral Anticoagulants (NOACs): Insights from a Meta-Analysis
    Parijat Sen, Amartya Kundu, Partha Sardar, Saurav Chatterjee, Ramez S. Nairooz, Hossam Amin, Wilbert S. Aronow · 2015 · American Journal of Cardiovascular Drugs
  33. HRS Policy Statement: Clinical Cardiac Electrophysiology Fellowship Curriculum: Update 2011
    Mark S. Link, Derek V. Exner, Mark E. Anderson, Michael Ackerman, Amin Al‐Ahmad, Bradley P. Knight, Steven M. Markowitz, Elizabeth S. Kaufman, David E. Haines, Samuel J. Asirvatham et al. · 2011 · Heart Rhythm
  34. Direct thrombin inhibitors and factor Xa inhibitors in patients with cerebrovascular disease
    Sarkis Morales‐Vidal, Michael J. Schneck, Murray S. Flaster, José Biller · 2012 · Expert Review of Neurotherapeutics
  35. Haemorragic and thromboembolic risk in CKD patients with non valvular atrial fibrillation: Do we need a novel risk score calculator?
    Maura Ravera, Elisabetta Bussalino, Ernesto Paoletti, Antonio Bellasi, Luca Di Lullo, Maria Fusaro · 2018 · International Journal of Cardiology
  36. Actualización detallada de las guías de la ESC para el manejo de la fibrilación auricular de 2012
    A. John Camm, Gregory Y.H. Lip, Raffaele De Caterina, Irene Savelieva, Dan Atar, Stefan Hans Hohnloser, Gerhard Hindricks, Paulus F. Kirchhof, Jeroen Joost Bax, Helmut Baumgartner et al. · 2012 · Revista Española de Cardiología
  37. Periprocedural Management of Oral Anticoagulation in Patients With Atrial Fibrillation: Approach in the Era of New Oral Anticoagulants
    Jeff S. Healey, Michela Brambatti · 2013 · Canadian Journal of Cardiology
  38. Tratamiento antiagregante plaquetario y anticoagulante para la prevención del ictus en pacientes con fibrilación auricular no valvular: nuevos avances basados en la evidencia
    Bernard John Gersh, Jane E. Freedman, Christopher Bull Granger · 2011 · Revista Española de Cardiología
  39. The Interaction Between Proton Pump Inhibitors and Clopidogrel and Upper Gastrointestinal Bleeding
    Grigorios I. Leontiadis, Yuhong Yuan, Colin W. Howden · 2011 · Gastrointestinal Endoscopy Clinics of North America
  40. Role of Emerging Antithrombotic Therapy in the Prevention of Cardioembolic Complications in Patients with Atrial Fibrillation
    PRAKASH C. DEEDWANIA, Grace W. Huang · 2011 · American Journal of Cardiovascular Drugs
  41. Novel Anticoagulants for Atrial Fibrillation
    Stylianos E. Tzeis, George K. Andrikopoulos · 2011 · Angiology
  42. Triple Oral Antithrombotic Therapy in Atrial Fibrillation and Coronary Artery Stenting: Searching for the Best Combination
    Hazem Fathy Elewa, Dina Ahmed, Geoffrey D. Barnes · 2016 · Seminars in Thrombosis and Hemostasis
  43. Trends in antithrombotic therapy for atrial fibrillation: Data from the Veterans Health Administration Health System
    Joshua Buck, Peter J. Kaboli, Brian F. Gage, Peter M Cram, Mary Vaughan‐Sarrazin · 2016 · American Heart Journal
  44. Minimizing bleeding risk in patients receiving direct oral anticoagulants for stroke prevention
    Jeffrey Habert · 2016 · International Journal of General Medicine
  45. Successful intravenous thrombolysis for ischemic stroke after reversal of dabigatran anticoagulation with idarucizumab: a case report
    Sergio Agosti, Laura Casalino, Enrico Rocci, Gabriele Zaccone, Eugenia Rota · 2017 · Journal of Medical Case Reports
  46. Predictors of Mortality in Patients With Atrial Fibrillation (from the Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events [ACTIVE A])
    Kanjana S. Perera, Lesly A. Pearce, Mukul Sharma, Oscar Benavente, Stuart J. Connolly, Robert G. Hart · 2017 · The American Journal of Cardiology
  47. Calibrated Automated Thrombinography (CAT), a Tool to Identify Patients at Risk of Bleeding during Anticoagulant Therapy: A Systematic Review
    Suzanne Zwaveling, Saartje Bloemen, Bas de Laat, Hugo Ten Cate, Arina J. ten Cate‐Hoek · 2018 · TH Open
  48. Left atrial appendage occlusion in recurrent ischaemic stroke, a multicentre experience
    Xavier Galloo, Tom Carmeliet, Edgard Alexander Prihadi, Stijn Lochy, Benjamin Scott, Stefan Verheye, D. Schoors, Paul H.M.J. Vermeersch · 2020 · Acta Clinica Belgica
  49. Antiplatelets in Secondary Stroke Prevention
    Olga D. Shulga, Natan M. Bornstein · 2011 · Frontiers in Neurology
  50. Effects of low-dose aspirin and fish oil on platelet function and NF-kappaB in adults with diabetes mellitus
    Robert Block, Amir Abdolahi, Brian Smith, Nida Meednu, Kelly N. Thevenet-Morrison, Xueya Cai, Huadong Cui, Shaker A. Mousa, James Thomas Brenna, Steve N. Georas · 2013 · Prostaglandins Leukotrienes and Essential Fatty Acids
  51. Risk factors for acute gastrointestinal bleeding following myocardial infarction in veteran patients who are prescribed clopidogrel
    Justin R. Cuschieri, Paul E. Drawz, Yngve T Falck-Ytter, Richard C.K. Wong · 2013 · Journal of Digestive Diseases
  52. Study of Clinical and Genetic Risk Factors for Aspirin-induced Gastric Mucosal Injury
    Yun Wu, Ying Chuan Hu, Peng You, Yujing Chi, Jianhua Zhou, Yuanyuan Zhang, Yulan Liu · 2016 · Chinese Medical Journal
  53. Gastrointestinal bleeding in patients receiving antiplatelet and anticoagulant therapy: practical guidance for restarting therapy and avoiding recurrences.
    Athanasios G. Pipilis, Stamatis S. Makrygiannis, Eleni Chrisanthopoulou, Nikolaos Sourlas, Sotirios Kaliambakos, Postolos Ntailianas · 2014 · PubMed
  54. Incidence and impact of atrial arrhythmias on thrombotic events in MPNs
    Kristell Mahé, Aurélien Delluc, Aurélie Chauveau, Philippe Castellant, Dominique Mottier, Florence Dalbiès, Christian Berthou, Gaëlle Guillerm, Éric Lippert, Jean‐Christophe Ianotto · 2017 · Annals of Hematology
  55. Stroke Risk and Treatment in Patients with Atrial Fibrillation and Low CHA 2 DS 2 ‐VASc Scores: Findings From the ORBIT‐AF I and II Registries
    Larry R. Jackson, Sunghee Kim, Gregg C. Fonarow, James V. Freeman, Bernard John Gersh, Alan S. Go, Elaine M. Hylek, Peter Russell Kowey, Kenneth W. Mahaffey, Daniel E. Singer et al. · 2018 · Journal of the American Heart Association
  56. A Pint of Sweat Will Save a Gallon of Blood
    Christopher Bull Granger, Glenn Matthew Chertow · 2014 · Circulation
  57. Dual Antiplatelet Therapy for the Acute Management and Long-term Secondary Prevention of Ischemic Stroke and Transient Ischemic Attack, An Updated Review
    Bernard Chan, Lily Y. H. Wong, Benjamin Yong‐Qiang Tan, Leonard L.L. Yeo, Narayanaswamy Venketasubramanian · 2024 · Journal of Cardiovascular Development and Disease
  58. Management of dabigatran-induced bleeding: expert statement
    Dietmar R. Fries, Alexander Giurea, Manfred Gütl, Walter‐Michael Halbmayer, Sibylle A. Kozek‐Langenecker, Andreas Pachucki, Franz Xaver Roithinger, Barbara Steinlechner, Heinrich Wolfgang Thaler, Ansgar Weltermann · 2013 · Wiener klinische Wochenschrift
  59. Management of Anticoagulation in Patients With Atrial Fibrillation
    Joshua D. Moss, Adam S. Cifu · 2015 · JAMA
  60. Prescribing proton pump inhibitor and clopidogrel together
    Neena S. Abraham · 2011 · Current Opinion in Gastroenterology
  61. Comparison of Frequency of Major Adverse Events in Patients With Atrial Fibrillation Receiving Bare-Metal Versus Drug-Eluting Stents in Their Coronary Arteries
    Laurent Fauchier, Céline Pellegrin, Anne Bernard, Nicolas Clémenty, Denis Angoulvant, Gregory Y.H. Lip, Dominique Babuty · 2012 · The American Journal of Cardiology
  62. Dual Antiplatelet Therapy of Clopidogrel and Aspirin in Secondary Prevention of Ischemic Stroke: Evidence and Indications
    Ya Su, Xin Cheng, Qiang Dong · 2015 · CNS Neuroscience & Therapeutics
  63. Expression of Protease Activated Receptor‐1 in Chronic Periodontitis
    Henrique Aparecido Bueno da Silva, Vanessa Tubero Euzébio Alves, Luís Carlos Spolidório, João Batista César Neto, Rosangela Aparecida dos Santos Eichler, Maria Helena Catelli de Carvalho, Marinella Holzhausen · 2014 · Journal of Periodontology
  64. Low dose dabigatran versus uninterrupted acenocoumarol for peri-procedural anticoagulation in atrial fibrillation catheter ablation
    Michael Efremidis, Konstantinos George Vlachos, Κonstantinos P. Letsas, Γεώργιος Γιαννόπουλος, Louiza Lioni, Stamatis Georgopoulos, Maria Vadiaka, Spyridon G. Deftereos, Antonios Sideris · 2015 · Journal of Electrocardiology
  65. A new era of stroke prevention in atrial fibrillation: comparing a new generation of oral anticoagulants with warfarin
    Bruce Sheldon Stambler · 2013 · International Archives of Medicine
  66. Systematic review and network meta-analysis of the relative efficacy and safety of edoxaban versus other nonvitamin K antagonist oral anticoagulants among patients with nonvalvular atrial fibrillation and CHADS 2 score ⩾ 2
    M. Fernandez, Jianmin Wang, Xin Ye, Winghan Jacqueline Kwong, Bintu N. Sherif, S. Hogue, Beth H Sherrill · 2015 · SAGE Open Medicine
  67. Impact of Baseline Stroke Risk and Bleeding Risk on Warfarin International Normalized Ratio Control in Atrial Fibrillation (from the TREAT-AF Study)
    Jessica A. Hellyer, Farnaz Azarbal, Claire T. Than, Jun Fan, Susan K. Schmitt, Felix Yang, Susan M. Frayne, Ciaran S. Phibbs, Celina Mei Yong, Paul A. Heidenreich et al. · 2016 · The American Journal of Cardiology
  68. Medikamenteninduzierte gastrointestinale Blutung
    Wolfgang Fischbach · 2019 · Der Internist
  69. Noncanonical Effects of Oral Thrombin and Factor Xa Inhibitors in Platelet Activation and Arterial Thrombosis
    Amin Polzin, Lisa Dannenberg, Manuela Thienel, Martin Orban, Georg Wolff, Thomas Hohlfeld, Tobias Zeus, Malte Kelm, Tobias Petzold · 2020 · Thrombosis and Haemostasis
  70. Micelle-Incorporated Liquid Chromatography in the Light of Green Chemistry: An Application for the Quality Control Analysis of Anti-Platelet Fixed-Dose Combinations
    Ahmed Elsonbaty, Wаfаа S. Hаssаn, Maya Shaaban Eissa, Sara Abdulwahab · 2022 · Journal of AOAC International
  71. Cognitive Impairment Is Not a Predictor of Failure to Adhere to Anticoagulation of Stroke Patients with Atrial Fibrillation
    Solveig Horstmann, Timolaos Rizos, Michaela Saribas, Evdokia Efthymiou, Geraldine Rauch, Roland C. Veltkamp · 2015 · Cerebrovascular Diseases
  72. Antithrombotic drugs in coronary artery disease: risk benefit ratio and bleeding
    Sam Schulman, Frederick Alan Spencer · 2010 · Journal of Thrombosis and Haemostasis
  73. The Evolving Field of Stroke Prevention in Patients With Atrial Fibrillation
    Michael D. Ezekowitz, Timothy H. Aikens, Annamarie Brown, Zack Ellis · 2010 · Stroke
  74. Managing peptic ulcer and gastroesophageal reflux disease in elderly Chinese patients – focus on esomeprazole
    Justin C. Y. Wu, Raymond S. Y. Tang · 2013 · Clinical Interventions in Aging
  75. Most Important Outcomes Research Papers on Anticoagulation for Cardiovascular Disease
    Behnood Bikdeli, Aakriti Gupta, Purav S. Mody, Julianna F. Lampropulos, Kumar Dharmarajan, for the Editor · 2012 · Circulation Cardiovascular Quality and Outcomes
  76. Dabigatran versus warfarin under standard or pharmacogenetic-guided management for the prevention of stroke and systemic thromboembolism in patients with atrial fibrillation: a cost/utility analysis using an analytic decision model
    Léon Nshimyumukiza, Julie Duplantie, Mathieu Gagnon, Xavier Douville, Diane Fournier, Carmen Lindsay, Marc Parent, Alain Milot, Yves Giguère, Christian Gagné et al. · 2013 · Thrombosis Journal
  77. New oral anticoagulants
    Eduard Shantsila, Gregory Y.H. Lip · 2010
  78. RE-ALIGN: First trial of novel oral anticoagulant in patients with mechanical heart valves – The search continues
    Ahmed Shazly, Ahmed Afifi · 2014 · Global Cardiology Science and Practice
  79. Ophthalmic Complications Associated with Direct Oral Anticoagulant Medications
    Wen-Shi Shieh, Jayanth S. Sridhar, Bryan Kun Hong, Joseph I. Maguire, Ehsan Rahimy, Abtin Shahlaee, Allen C. Ho, Jason Hsu, Carl D. Regillo, Allen Chiang · 2016 · Seminars in Ophthalmology
  80. Major bleeding with old and novel oral anticoagulants: How to manage it. Focus on reversal agents
    Stefania Angela Di Fusco, Fabiana Lucà, Manuela Benvenuto, Annamaria Iorio, Damiana Fiscella, Fabrizio D’Ascenzo, Andrea Madeo, Furio Colivicchi, Andrea Di Lenarda, Michele Massimo Gulizia · 2018 · International Journal of Cardiology
  81. Gleichzeitige Anwendung von Thrombozytenaggregationshemmern und Protonenpumpeninhibitoren (PPIs)
    W. Fischbach, Harald Darius, Marie Michelle Gross, Herbert Koop, Irmtraut Kruck, K. Petersen · 2010 · Zeitschrift für Gastroenterologie
  82. Contra: “Anti-platelet therapy is an alternative to oral anticoagulation for atrial fibrillation”
    Stavros Z. Apostolakis, Eduard Shantsila, Gregory Y.H. Lip, Deirdre A. Lane · 2009 · Thrombosis and Haemostasis
  83. J-ROCKET AF Trial Increased Expectation of Lower-Dose Rivaroxaban Made for Japan
    Masahiro Yasaka · 2012 · Circulation Journal
  84. Long-Term Anticoagulation for Patients Receiving Dialysis
    Sagar U. Nigwekar, Ravi Thadhani · 2018 · Circulation
  85. Home-monitoring of oral anticoagulation vs. dabigatran
    Qi Xin Zhou, Gordon Henry Guyatt, Pablo Alonso‐Coello · 2012 · Thrombosis and Haemostasis
  86. Efficacy and Safety of Adding Clopidogrel to Aspirin on Stroke Prevention among High Vascular Risk Patients: A Meta-Analysis of Randomized Controlled Trials
    Shuying Chen, Qingyu Shen, Yamei Tang, Lei He, Yi Li, Hui Li, Mei Li, Ying Peng · 2014 · PLoS ONE
  87. Stroke Prevention in Patients With Atrial Fibrillation and Renal Dysfunction
    Scott Kaatz, Charles Edward Mahan · 2014 · Stroke
  88. Appropriateness of Dabigatran and Rivaroxaban Prescribing for Hospital Inpatients
    Unnum Chowdhry, Amanda Jacques, Alan J. Karovitch, Pierre Giguère, My-Linh Nguyen · 2016 · The Canadian Journal of Hospital Pharmacy
  89. Prevention and Treatment of Bleeding with Direct Oral Anticoagulants
    R. Monroe Crawley, Rachel Lynn Anderson · 2020 · Drugs
  90. Antithrombotic Therapy in the Prevention of Stroke
    Shyamal C. Bir, Roger E. Kelley · 2021 · Biomedicines
  91. Artificial-Intelligence-Assisted Discovery of Genetic Factors for Precision Medicine of Antiplatelet Therapy in Diabetic Peripheral Artery Disease
    Chi‐Hsiao Yeh, Yi-Ju Chou, Tsung-Hsien Tsai, Paul Wei-Che Hsu, Chun‐Hsien Li, Yun-Hsuan Chan, Shih‐Feng Tsai, Soh‐Ching Ng, Kuei-Mei Chou, Yu‐Ching Lin et al. · 2022 · Biomedicines
  92. Plasma angiopoietin-2 and its association with heart failure in patients with atrial fibrillation
    Alexander Philipp Benz, Ziad Hijazi, Johan Lindbäck, Stuart J. Connolly, John W. Eikelboom, Peter Kastner, André Ziegler, John Hunter Alexander, Christopher Bull Granger, Renato D. Lópes et al. · 2023 · EP Europace
  93. Chinese Guidelines for the Diagnosis and Management of Atrial Fibrillation
    Changsheng Ma, Shulin Wu, Shaowen Liu, Yaling Han · 2024 · 老年心脏病学杂志：英文版
  94. Anti‐platelet therapy and managing ulcer risk
    Francis K.L. Chan · 2011 · Journal of Gastroenterology and Hepatology
  95. Non-vitamin K Antagonist Oral Anticoagulants (NOACs): a View from the Laboratory
    Andrew D. Blann · 2014 · British Journal of Biomedical Science
  96. Novel nonpharmacologic approaches for stroke prevention in atrial fibrillation: results from clinical trials
    Vidal Essebag, Jacqueline E. Joza, Andrea Arensi, Micheal Levi, Vincenzo Russo, Apostolos Tzikas, Paolo Danna, Antonio Sagone, Maurizio Viecca, Riccardo Proietti · 2015 · Medical Devices Evidence and Research
  97. CYP2C19 Genotype and Cardiovascular Events—Reply
    Aroon Dinesh Hingorani · 2012 · JAMA
  98. Percutaneous coronary intervention and atrial fibrillation: the triple therapy dilemma
    J. Cho, D. Angiolillo · 2015 · Journal of Thrombosis and Thrombolysis
  99. Relation Between Dabigatran Concentration, as Assessed Using the Direct Thrombin Inhibitor Assay, and Activated Clotting Time/Activated Partial Thromboplastin Time in Patients With Atrial Fibrillation
    Kenji Okubo, Taishi Kuwahara, Katsumasa Takagi, Masateru Takigawa, Jun Nakajima, Yuji Watari, Emiko Nakashima, Kazuya Yamao, Tadashi Fujino, Hiroyuki Tsutsui et al. · 2015 · The American Journal of Cardiology
  100. Clinical Significance of Non-Vitamin K Antagonist Oral Anticoagulants in the Management of Atrial Fibrillation
    Giuseppe Santarpia, Antonio Curcio, Gerolamo Sibilio, Ciro Indolfi · 2015 · Circulation Journal